Antimicrobial Exposure and Risk for Incident Major Depressive Disorder.

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Journal of Clinical Psychopharmacology Pub Date : 2025-05-01 Epub Date: 2025-04-07 DOI:10.1097/JCP.0000000000002004
Hope Thelander, Brett Heintz, Lucas Watson, Bruce Alexander, Brian C Lund
{"title":"Antimicrobial Exposure and Risk for Incident Major Depressive Disorder.","authors":"Hope Thelander, Brett Heintz, Lucas Watson, Bruce Alexander, Brian C Lund","doi":"10.1097/JCP.0000000000002004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antibacterials are among the most frequently prescribed medications. Antibacterial drugs have the unintended consequence of destroying healthy gut flora, which can lead to known adverse events such as Clostridium difficile infection. Given emerging research concerning the role of these microorganisms in the gut-brain axis and some limited epidemiological studies, the objective of this study was to determine if antimicrobial exposure is associated with increased risk for depression.</p><p><strong>Methods: </strong>National Veterans Health Administration administrative data were used to identify 878,405 veteran patients prescribed an incident antimicrobial during calendar year 2018. Sequence symmetry analysis was used to compare the incidence of a depressive disorder in the 6 months before and after antibacterial exposure, with additional analyses conducted with other antimicrobial classes as negative controls including antifungals, antivirals, and nonsystemic antibacterials.</p><p><strong>Results: </strong>Antibacterial initiation was associated with a small but significant increase in the risk of incident depression (symmetry ratio [SR] = 1.04, 95% confidence interval [CI]: 1.03, 1.05), which was limited to the first 8 weeks following exposure. The strength of association varied with categories of antibacterial spectrum, from SR = 0.98 (95% CI: 0.95, 1.01) with the narrowest spectrum regimens, to SR = 1.12 (95% CI: 1.09, 1.15) with the broadest regimens. No significant association with incident depression was observed for antifungals, antivirals, and nonsystemic antibacterials.</p><p><strong>Conclusions: </strong>Antibacterial exposure was associated with increased risk for a depressive disorder. These findings are consistent with emerging literature and support the need for further research investigating a causal relationship between antibacterial exposure and risk for adverse mental health outcomes.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"219-224"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000002004","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Antibacterials are among the most frequently prescribed medications. Antibacterial drugs have the unintended consequence of destroying healthy gut flora, which can lead to known adverse events such as Clostridium difficile infection. Given emerging research concerning the role of these microorganisms in the gut-brain axis and some limited epidemiological studies, the objective of this study was to determine if antimicrobial exposure is associated with increased risk for depression.

Methods: National Veterans Health Administration administrative data were used to identify 878,405 veteran patients prescribed an incident antimicrobial during calendar year 2018. Sequence symmetry analysis was used to compare the incidence of a depressive disorder in the 6 months before and after antibacterial exposure, with additional analyses conducted with other antimicrobial classes as negative controls including antifungals, antivirals, and nonsystemic antibacterials.

Results: Antibacterial initiation was associated with a small but significant increase in the risk of incident depression (symmetry ratio [SR] = 1.04, 95% confidence interval [CI]: 1.03, 1.05), which was limited to the first 8 weeks following exposure. The strength of association varied with categories of antibacterial spectrum, from SR = 0.98 (95% CI: 0.95, 1.01) with the narrowest spectrum regimens, to SR = 1.12 (95% CI: 1.09, 1.15) with the broadest regimens. No significant association with incident depression was observed for antifungals, antivirals, and nonsystemic antibacterials.

Conclusions: Antibacterial exposure was associated with increased risk for a depressive disorder. These findings are consistent with emerging literature and support the need for further research investigating a causal relationship between antibacterial exposure and risk for adverse mental health outcomes.

抗微生物药物暴露与发生重度抑郁症的风险。
背景:抗菌药物是最常用的处方药之一。抗菌药物具有破坏健康肠道菌群的意想不到的后果,这可能导致已知的不良事件,如艰难梭菌感染。鉴于有关这些微生物在肠-脑轴中的作用的新兴研究和一些有限的流行病学研究,本研究的目的是确定抗菌药物暴露是否与抑郁症风险增加有关。方法:利用国家退伍军人卫生管理局的管理数据,对2018年服用意外抗菌药物的878,405名退伍军人患者进行鉴定。序列对称分析用于比较抗菌药物暴露前后6个月内抑郁症的发病率,并对其他抗菌药物类别进行了额外的分析,作为阴性对照,包括抗真菌药物、抗病毒药物和非全身性抗菌药物。结果:开始使用抗菌药物与发生抑郁的风险增加相关(对称比[SR] = 1.04, 95%可信区间[CI]: 1.03, 1.05),这仅限于接触后的前8周。相关强度随抗菌谱类别的不同而不同,从最窄谱方案的SR = 0.98 (95% CI: 0.95, 1.01)到最广方案的SR = 1.12 (95% CI: 1.09, 1.15)。抗真菌药物、抗病毒药物和非全身性抗菌药物与抑郁症发生率无显著关联。结论:抗菌药物暴露与抑郁症风险增加有关。这些发现与新兴文献一致,并支持进一步研究抗菌药物暴露与不良心理健康结果风险之间的因果关系的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
3.40%
发文量
231
审稿时长
4-8 weeks
期刊介绍: Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信